2023-09-25 19:35:00
Anvisa, the National Health Surveillance Agency, approved this Monday (25) a new medicine for the treatment of type 2 diabetes, Mounjaro, from the pharmaceutical company Eli Lily.
Similar to the well-known Ozempic, from Nordisk, tirzepatide is an injectable medication, administered weekly, that acts on the receptors of two hormones produced naturally in the body, GLP-1 (glucagon-like peptide 1) and GIP (insulin-dependent polypeptide). of glucose), responsible for controlling blood glycemic levels and the feeling of satiety. During the studies, Mounjaro had better results in this regard.
The drug helped release insulin, in addition to regulating appetite, providing results considered unprecedented by pharmaceuticals. This seems to have happened because Ozempic, that is, semaglutide, only acts on GLP-1, just one of the hormones on which Mounjaro acts.
In a phase three clinical trial, which included almost 1,900 participants, tirzepatide achieved a better reduction in sugar levels in patients with type 2 diabetes in up to eight weeks, comparing different dosages of tirzepatide (5, 10 and 15 mg) with 1 mg semaglutide. In addition to Brazil, Mounjaro is released in the United States and Europe.
1695688819
#Anvisa #approves #Mounjaro #injectable #medicine #treat #type #diabetes
